// App-Quantinova.ai

240 : Analysis of the temporal relationship between patient-reported outcomes (PROs) and overall survival (OS) and radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).

Researchers

Presenter

  • Shana Traina

Principal Investigators

  • Tracy Li

  • Kristen Johnson

  • Kai Fai Ho

  • Arturo Molina

  • David Cella

Medical Centers

  • Janssen Global Services, Raritan, NJ

  • STAT-TU Inc., Toronto, ON, Canada

  • Janssen Research & Development, Menlo Park, CA

  • Northwestern University, Chicago, IL

Locations

  • United States

  • Canada

Companies

  • STAT-TU Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT00887198

  • NCT00638690

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved